Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
kennedykrieger.orgLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
76
Active
25
Phase 3
2
Total enrollment
15,170
Pipeline matrix
Showing 2 of 2 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| methylphenidate hydrochloride | — | — | — | — | — | 1 | |
| Melatonin | — | — | — | — | — | 1 |
Next readouts
- 2028-07-01
- 2030-12
Top conditions
- Autism Spectrum Disorder12
- ADHD6
- Anxiety5
- Spinal Cord Injury5
- Cerebellar Ataxia4
- Spinal Cord Injuries4
- Stroke3
- Hemiparesis3
Frequently asked questions about Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
- How many clinical trials does Hugo W. Moser Research Institute at Kennedy Krieger, Inc. have on ClinicalTrials.gov?
- Hugo W. Moser Research Institute at Kennedy Krieger, Inc. is listed as the lead sponsor on 76 clinical trials in ClinicalTrials.gov, 25 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Hugo W. Moser Research Institute at Kennedy Krieger, Inc.'s trials are in Phase 3?
- 2 of Hugo W. Moser Research Institute at Kennedy Krieger, Inc.'s trials are in Phase 3, spread across 2 active drug programs.
- What therapeutic areas does Hugo W. Moser Research Institute at Kennedy Krieger, Inc. focus on?
- Hugo W. Moser Research Institute at Kennedy Krieger, Inc.'s most-studied conditions on ClinicalTrials.gov are Autism Spectrum Disorder, ADHD, Anxiety, Spinal Cord Injury, Cerebellar Ataxia.
- When are Hugo W. Moser Research Institute at Kennedy Krieger, Inc.'s next clinical trial readouts?
- Hugo W. Moser Research Institute at Kennedy Krieger, Inc. has 2 upcoming primary-completion readouts tracked here; the soonest is “Melatonin for the Treatment of DEE-SWAS”, expected around 2028-07-01.